Investment to support the continued evaluation and redevelopment of KALA’s product candidates and patent portfolio, and provide working capital and funding for a potential future strategic transactionARLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, announces it has entered into a $6 million securities purchas ...